NIOX Group (LON:NIOX) Issues Quarterly Earnings Results

Key Points

• NIOX Group reported earnings of GBX 1.43 per share for the quarter, alongside a return on equity of 13.29% and a net margin of 28.21%.
• Despite the positive earnings, NIOX Group's stock fell 0.5% during Tuesday's trading, opening at GBX 73.06.
• The company is focused on non-invasive diagnostic products for chronic airway diseases and operates in over 50 countries globally.

NIOX Group (LON:NIOX - ) posted its earnings results on Tuesday. The company reported GBX 1.43 earnings per share for the quarter, Digital Look Earnings reports. NIOX Group had a return on equity of 13.29% and a net margin of 28.21%.

NIOX Group Stock Down 0.5%

NIOX opened at GBX 73.06 on Tuesday. The business has a 50 day moving average price of GBX 71.09 and a 200 day moving average price of GBX 68.43. NIOX Group has a twelve month low of GBX 53.40 and a twelve month high of GBX 80. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.94 and a current ratio of 6.31. The firm has a market cap of £305.24 million, a P/E ratio of 8,801.81 and a beta of 0.92.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.